

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

December 17, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 13, 2012

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**

*(State or Other Jurisdiction  
Of Incorporation)*

**001-34236**

*(Commission File Number)*

**11-3054851**

*(I.R.S. Employer  
Identification No.)*

**35 Wilbur Street**

**Lynbrook, NY 11563**

*(Address of Principal Executive Office) (Zip Code)*

**516.593.7000**

*(Registrant's telephone number, including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

## **INTRODUCTORY COMMENT**

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

## **ITEM 8.01 OTHER EVENTS**

On December 13, 2012, the Company announced top-line 30-day data from the Phase Ib study of XIAFLEX for the potential treatment of adult patients with edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite, which is being conducted by BioSpecifics partner Auxilium Pharmaceuticals, Inc.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

## **ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

99.1 Press release dated December 13, 2012

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 14, 2012

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Registrant)

/s/ Thomas L. Wegman

Thomas L. Wegman  
President

---